Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia
- PMID: 11784876
- DOI: 10.1056/NEJMoa011262
Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia
Erratum in
- N Engl J Med 2002 May 23;346(21):1678
Abstract
Background: Progressive osseous heteroplasia (POH), an autosomal dominant disorder, is characterized by extensive dermal ossification during childhood, followed by disabling and widespread heterotopic ossification of skeletal muscle and deep connective tissue. Occasional reports of mild heterotopic ossification in Albright's hereditary osteodystrophy (AHO) and a recent report of two patients with AHO who had atypically extensive heterotopic ossification suggested a common genetic basis for the two disorders. AHO is caused by heterozygous inactivating mutations in the GNAS1 gene that result in decreased expression or function of the alpha subunit of the stimulatory G protein (Gsalpha) of adenylyl cyclase.
Methods: We tested the hypothesis that GNAS1 mutations cause POH, using the polymerase chain reaction to amplify GNAS1 exons and exon-intron boundaries in 18 patients with sporadic or familial POH.
Results: Heterozygous inactivating GNAS1 mutations were identified in 13 of the 18 probands with POH. The defective allele in POH is inherited exclusively from fathers, a result consistent with a model of imprinting for GNAS1. Direct evidence that the same mutation can cause either POH or AHO was observed within a single family, in which the phenotype correlated with the parental origin of the mutant allele.
Conclusions: Paternally inherited inactivating GNAS1 mutations cause POH. This finding extends the range of phenotypes derived from haplo insufficiency of GNAS1, provides evidence that imprinting is a regulatory mechanism for GNAS1 expression, and suggests that Gsalpha is a critical negative regulator of osteogenic commitment in nonosseous connective tissues.
Comment in
-
The genetic basis of progressive osseous heteroplasia.N Engl J Med. 2002 Jan 10;346(2):128-30. doi: 10.1056/NEJM200201103460212. N Engl J Med. 2002. PMID: 11784882 No abstract available.
-
GNAS1 mutations and progressive osseous heteroplasia.N Engl J Med. 2002 May 23;346(21):1669-71. doi: 10.1056/NEJM200205233462115. N Engl J Med. 2002. PMID: 12024004 No abstract available.
-
GNAS1 mutations and progressive osseous heteroplasia.N Engl J Med. 2002 May 23;346(21):1669-71. N Engl J Med. 2002. PMID: 12030264 No abstract available.
Similar articles
-
Progressive osseous heteroplasia.J Bone Miner Res. 2000 Nov;15(11):2084-94. doi: 10.1359/jbmr.2000.15.11.2084. J Bone Miner Res. 2000. PMID: 11092391 Review.
-
GNAS1 mutation and Cbfa1 misexpression in a child with severe congenital platelike osteoma cutis.J Bone Miner Res. 2000 Nov;15(11):2063-73. doi: 10.1359/jbmr.2000.15.11.2063. J Bone Miner Res. 2000. PMID: 11092389
-
Progressive osseous heteroplasia resulting from a new mutation in the GNAS1 gene.Clin Exp Dermatol. 2004 Jan;29(1):77-80. doi: 10.1111/j.1365-2230.2004.01439.x. Clin Exp Dermatol. 2004. PMID: 14723729
-
Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series.Bone. 2013 Oct;56(2):276-80. doi: 10.1016/j.bone.2013.06.015. Epub 2013 Jun 21. Bone. 2013. PMID: 23796510
-
GNAS mutations and heterotopic ossification.Bone. 2018 Apr;109:80-85. doi: 10.1016/j.bone.2017.09.002. Epub 2017 Sep 6. Bone. 2018. PMID: 28889026 Free PMC article. Review.
Cited by
-
Revisiting Heinz-Lippman disease as a complication of chronic venous insufficiency.J Vasc Surg Cases Innov Tech. 2023 Dec 29;10(2):101408. doi: 10.1016/j.jvscit.2023.101408. eCollection 2024 Apr. J Vasc Surg Cases Innov Tech. 2023. PMID: 38389931 Free PMC article.
-
Enhancer hijacking at the ARHGAP36 locus is associated with connective tissue to bone transformation.Nat Commun. 2023 Apr 11;14(1):2034. doi: 10.1038/s41467-023-37585-8. Nat Commun. 2023. PMID: 37041138 Free PMC article.
-
A Novel De Novo Frameshift Pathogenic Variant in the FAM111B Resulting in Progressive Osseous Heteroplasia Phenotype.Calcif Tissue Int. 2023 Apr;112(4):518-523. doi: 10.1007/s00223-022-01053-0. Epub 2022 Dec 27. Calcif Tissue Int. 2023. PMID: 36575358
-
Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia.Front Pediatr. 2022 Nov 22;10:936780. doi: 10.3389/fped.2022.936780. eCollection 2022. Front Pediatr. 2022. PMID: 36483469 Free PMC article.
-
Dynamic Balance between PTH1R-Dependent Signal Cascades Determines Its Pro- or Anti-Osteogenic Effects on MSC.Cells. 2022 Nov 7;11(21):3519. doi: 10.3390/cells11213519. Cells. 2022. PMID: 36359914 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases